CicadaBio Presents Novel Preclinical Data for CC-18, a GLP-1/ActRII Fusion Protein Designed for Muscle-Preserving Weight Loss, at ADA 2026

Business Wire USA

Overview

CicadaBio orally presented novel preclinical data for CC-18, a first-in-class GLP-1/ActRII fusion protein designed for muscle-preserving weight loss, at the American Diabetes Association (ADA) 2026 Scientific Sessions. CC-18 is a fusion protein targeting dual GLP-1 and anti-ActRII pathways, representing an innovative approach to maintain muscle mass while achieving weight reduction. This holds the potential to establish a new paradigm in obesity treatment.

In Depth

Key Findings

CicadaBio orally presented novel preclinical data for CC-18, a first-in-class GLP-1/ActRII fusion protein designed for muscle-preserving weight loss, at the American Diabetes Association (ADA) 2026 Scientific Sessions. This presentation introduces an innovative solution to the challenge of ‘maintaining muscle mass during weight loss,’ a difficulty often encountered with existing weight management therapies.

Technical / Clinical Details

CC-18 is a dual-acting fusion protein that combines the effects of a GLP-1 (Glucagon-Like Peptide-1) receptor agonist with activin receptor type II (ActRII) inhibition. While the GLP-1 action promotes weight reduction through appetite suppression and glycemic control, the simultaneous ActRII inhibition aims to counteract muscle catabolism, thereby preventing muscle mass loss during weight reduction. Preclinical studies in animal models (e.g., obese mice, non-human primates) demonstrated that CC-18 administration achieved significant weight loss while simultaneously maintaining or increasing muscle mass, compared to placebo or single-acting GLP-1 agonists. Selective reduction of fat mass was also observed, suggesting potential contributions to improved metabolic profiles.

Background & Context

Obesity is a global health challenge that increases the risk of cardiovascular disease, diabetes, and certain cancers. While GLP-1 receptor agonists are highly regarded for their weight loss efficacy, a challenge has been that their effects include not only fat mass reduction but also some degree of muscle mass loss. Muscle loss during weight reduction can lead to decreased basal metabolic rate and physical function, potentially increasing the risk of weight regain. The development of muscle-preserving weight loss drugs like CC-18 addresses a critical unmet medical need for patients seeking healthier and more sustainable weight management solutions.

Strategic Significance & Outlook

The presentation of CC-18 at ADA 2026 could mark the beginning of a new paradigm in obesity treatment. Based on these promising preclinical data, CicadaBio will now accelerate the clinical development of CC-18, aiming for human proof-of-concept. If clinical trials confirm similar muscle-preserving weight loss effects, CC-18 is expected to become a strong differentiator in the obesity drug market and a groundbreaking therapy that significantly improves patients’ quality of life. This demonstrates the great potential of multifunctional fusion proteins in addressing complex metabolic disease challenges.